Arch Biopartners Inc logo

ARCH - Arch Biopartners Inc Share Price

C$1.33 -0.1  -4.3%

Last Trade - 14/04/21

Micro Cap
Market Cap £47.4m
Enterprise Value £49.0m
Revenue £22.2k
Position in Universe 938th / 2712
Unlock ARCH Revenue
Relative Strength (%)
1m +5.19%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -21.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Sep 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.038 0.000 0.000 0.000 0.094 0.068 +12.5%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 December 2020, ArchBiopartners Inc revenues decreased from C$26K to C$0K. Netloss increased from C$733K to C$1.7M. Revenues reflect adecrease in demand for the Company's products and servicesdue to unfavorable market conditions. Higher net lossreflects Research increase from C$576K to C$1.3M (expense),Share-based payments increase from C$11K to C$85K (expense), Professional fees increase from C$27K to C$94K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ARCH
Graphical History


ARCH Revenue Unlock ARCH Revenue

Net Income

ARCH Net Income Unlock ARCH Revenue

Normalised EPS

ARCH Normalised EPS Unlock ARCH Revenue

PE Ratio Range

ARCH PE Ratio Range Unlock ARCH Revenue

Dividend Yield Range

ARCH Dividend Yield Range Unlock ARCH Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ARCH EPS Forecasts Unlock ARCH Revenue
Profile Summary

Arch Biopartners Inc. is a portfolio-based biotechnology company. The Company is focused on the development of technologies that make a medical or commercial impact. Its technology platforms include AB569, MetaBlok, Arch Inflammation, Borg and MetaMx. AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and urinary tract. MetaBlok is a drug candidate targeting sepsis, cancer metastasis and inflammation based diseases. Arch Inflammation is a treatment for chronic kidney and bowel diseases caused by non-infectious inflammation. Arch Inflammation is focused on developing anti-inflammatory small molecules that target proteins in the innate immune system. Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation. MetaMx are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The Company has not generated any revenues.

Last Annual September 30th, 2020
Last Interim December 31st, 2020
Incorporated November 13, 2003
Public Since October 9, 1996
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange TSX Venture Exchange
Shares in Issue 61,462,302
Free Float (0.0%)
Eligible for
ARCH Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ARCH
Upcoming Events for ARCH
Frequently Asked Questions for Arch Biopartners Inc
What is the Arch Biopartners Inc share price?

As of 14/04/21, shares in Arch Biopartners Inc are trading at C$1.33, giving the company a market capitalisation of £47.4m. This share price information is delayed by 15 minutes.

How has the Arch Biopartners Inc share price performed this year?

Shares in Arch Biopartners Inc are currently trading at C$1.33 and the price has moved by 50.55% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Arch Biopartners Inc price has moved by 9.43% over the past year.

What are the analyst and broker recommendations for Arch Biopartners Inc?

There are no analysts currently covering Arch Biopartners Inc.

When will Arch Biopartners Inc next release its financial results?

Arch Biopartners Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Arch Biopartners Inc dividend yield?

Arch Biopartners Inc does not currently pay a dividend.

Does Arch Biopartners Inc pay a dividend?

Arch Biopartners Inc does not currently pay a dividend.

When does Arch Biopartners Inc next pay dividends?

Arch Biopartners Inc does not currently pay a dividend.

How do I buy Arch Biopartners Inc shares?

To buy shares in Arch Biopartners Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Arch Biopartners Inc?

Shares in Arch Biopartners Inc are currently trading at C$1.33, giving the company a market capitalisation of £47.4m.

Where are Arch Biopartners Inc shares listed? Where are Arch Biopartners Inc shares listed?

Here are the trading details for Arch Biopartners Inc:

Country of listing: Canada
Exchange: CVE
Ticker Symbol: ARCH
What kind of share is Arch Biopartners Inc?

Based on an overall assessment of its quality, value and momentum, Arch Biopartners Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Arch Biopartners Inc share price forecast 2021?

We were not able to load any forecast data for Arch Biopartners Inc.

How can I tell whether the Arch Biopartners Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arch Biopartners Inc. Over the past six months, the relative strength of its shares against the market has been -25.58%. At the current price of C$1.33, shares in Arch Biopartners Inc are trading at -4% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Arch Biopartners Inc PE Ratio?

We were not able to find PE ratio data for Arch Biopartners Inc.

Who are the key directors of Arch Biopartners Inc?

Arch Biopartners Inc's management team is headed by:

Richard Muruve - CEO
Richard Rossman - DRC
Andrew Bishop - DRC
Claude Allary - IND
Adrian Haigh - IND
Daniel Muruve - CSO
Who are the major shareholders of Arch Biopartners Inc?

Here are the top five shareholders of Arch Biopartners Inc based on the size of their shareholding:

Muruve (Richard) Individual Investor
Percentage owned: 14.7% (9.04m shares)
McElroy (Carol) Individual Investor
Percentage owned: 9.37% (5.76m shares)
Rossman (Richard) Individual Investor
Percentage owned: 3.58% (2.20m shares)
Bishop (Andrew) Individual Investor
Percentage owned: 0.7% (430k shares)
Allary (Claude) Individual Investor
Percentage owned: 0.26% (157k shares)
Similar to ARCH
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.